Tags

Type your tag names separated by a space and hit enter

Characterization of osteoarthritis in cats and meloxicam efficacy using objective chronic pain evaluation tools.
Vet J 2013; 196(3):360-7VJ

Abstract

This study aimed to characterize osteoarthritis (OA)-related chronic pain and disability in experimental cats with naturally occurring OA. Peak vertical ground reaction force (PVF), accelerometer-based motor activity (MA) and the von Frey anesthesiometer-induced paw withdrawal threshold were used to define OA and to test the efficacy of meloxicam. A diagnosis of OA was based on radiographic and orthopedic examinations. Cats with OA (n=39) and classified as non-OA (n=6) were used to assess the reliability and sensitivity of the parameters to assess OA over 3weeks while being administered placebo medication. A randomised parallel design study was then used to investigate the effects on OA of daily oral meloxicam treatment for 4weeks at different dose rates (0.025mg/kg, n=10mg/kg; 0.04mg/kg, n=10; 0.05mg/kg, n=9), compared to cats administered a placebo (n=10). The test-retest repeatability for each tool was good (intra-class correlation coefficient ⩾0.6). The PVF and the von Frey anesthesiometer-induced paw withdrawal threshold discriminated OA (P<0.05). Meloxicam did not add to the PVF improvement observed in placebo-treated cats during the treatment period (adj-P⩽0.01). The 0.025 and the 0.05mg/kg meloxicam-treated cats experienced a higher night-time (17:00-06:58h) MA intensity during the treatment period compared to the placebo period (adj-P=0.04, and 0.02, respectively) and this effect was not observed in the placebo group. The high allodynia rate observed in the 0.04mg/kg meloxicam-treated group may explain the lower responsiveness to the drug. The von Frey anesthesiometer-induced paw withdrawal threshold demonstrated no responsiveness to meloxicam. The results from this study indicated that daily oral meloxicam administration for 4weeks provided pain relief according to night-time MA.

Authors+Show Affiliations

Groupe de Recherche en Pharmacologie Animale du Québec (GREPAQ), Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, QC, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23416029

Citation

Guillot, M, et al. "Characterization of Osteoarthritis in Cats and Meloxicam Efficacy Using Objective Chronic Pain Evaluation Tools." Veterinary Journal (London, England : 1997), vol. 196, no. 3, 2013, pp. 360-7.
Guillot M, Moreau M, Heit M, et al. Characterization of osteoarthritis in cats and meloxicam efficacy using objective chronic pain evaluation tools. Vet J. 2013;196(3):360-7.
Guillot, M., Moreau, M., Heit, M., Martel-Pelletier, J., Pelletier, J. P., & Troncy, E. (2013). Characterization of osteoarthritis in cats and meloxicam efficacy using objective chronic pain evaluation tools. Veterinary Journal (London, England : 1997), 196(3), pp. 360-7. doi:10.1016/j.tvjl.2013.01.009.
Guillot M, et al. Characterization of Osteoarthritis in Cats and Meloxicam Efficacy Using Objective Chronic Pain Evaluation Tools. Vet J. 2013;196(3):360-7. PubMed PMID: 23416029.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characterization of osteoarthritis in cats and meloxicam efficacy using objective chronic pain evaluation tools. AU - Guillot,M, AU - Moreau,M, AU - Heit,M, AU - Martel-Pelletier,J, AU - Pelletier,J-P, AU - Troncy,E, Y1 - 2013/02/14/ PY - 2012/05/11/received PY - 2012/12/20/revised PY - 2013/01/14/accepted PY - 2013/2/19/entrez PY - 2013/2/19/pubmed PY - 2013/12/24/medline SP - 360 EP - 7 JF - Veterinary journal (London, England : 1997) JO - Vet. J. VL - 196 IS - 3 N2 - This study aimed to characterize osteoarthritis (OA)-related chronic pain and disability in experimental cats with naturally occurring OA. Peak vertical ground reaction force (PVF), accelerometer-based motor activity (MA) and the von Frey anesthesiometer-induced paw withdrawal threshold were used to define OA and to test the efficacy of meloxicam. A diagnosis of OA was based on radiographic and orthopedic examinations. Cats with OA (n=39) and classified as non-OA (n=6) were used to assess the reliability and sensitivity of the parameters to assess OA over 3weeks while being administered placebo medication. A randomised parallel design study was then used to investigate the effects on OA of daily oral meloxicam treatment for 4weeks at different dose rates (0.025mg/kg, n=10mg/kg; 0.04mg/kg, n=10; 0.05mg/kg, n=9), compared to cats administered a placebo (n=10). The test-retest repeatability for each tool was good (intra-class correlation coefficient ⩾0.6). The PVF and the von Frey anesthesiometer-induced paw withdrawal threshold discriminated OA (P<0.05). Meloxicam did not add to the PVF improvement observed in placebo-treated cats during the treatment period (adj-P⩽0.01). The 0.025 and the 0.05mg/kg meloxicam-treated cats experienced a higher night-time (17:00-06:58h) MA intensity during the treatment period compared to the placebo period (adj-P=0.04, and 0.02, respectively) and this effect was not observed in the placebo group. The high allodynia rate observed in the 0.04mg/kg meloxicam-treated group may explain the lower responsiveness to the drug. The von Frey anesthesiometer-induced paw withdrawal threshold demonstrated no responsiveness to meloxicam. The results from this study indicated that daily oral meloxicam administration for 4weeks provided pain relief according to night-time MA. SN - 1532-2971 UR - https://www.unboundmedicine.com/medline/citation/23416029/Characterization_of_osteoarthritis_in_cats_and_meloxicam_efficacy_using_objective_chronic_pain_evaluation_tools_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1090-0233(13)00018-X DB - PRIME DP - Unbound Medicine ER -